Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Acute Cardiorenal Syndrome
NCT07273838Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Mar 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Acute Cardiorenal Syndrome comparing Dapagliflozin 10mg with Placebo (2 arms). Primary endpoint: Cardio-renal clinical improvement calculated as a Win Ratio at 30 days. Started Mar 2026; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
Acute Cardiorenal Syndrome
Beyond the preview
Go deeper on NCT07273838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07273838.